Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)
Summary
3/13/2018 NOTE: There are limited slots available on a monthly basis for this trial.
The purpose of this phase Ib/II trial is to confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with locally advanced or metastatic pancreatic cancer who have received at least one dose of first line chemotherapy and may have responding, stable or progressive disease.
General Information
NCT#: NCT03269526
Study ID: 19236
Trial Phase: Phase I/II
Trial Sponsor: University of Virginia
Therapies Used in This Trial: anti-CD3 x anti-EGFR Bispecific antibody Armed T cells (EGFR BATs)